Skip Navigation



European Heart Journal Advance Access published online on October 28, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn489
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/23/2827    most recent
ehn489v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gravning, J.
Right arrow Articles by Kjekshus, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gravning, J.
Right arrow Articles by Kjekshus, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

The perfect biomarker in acute coronary syndrome: a challenge for diagnosis, prognosis, and treatment

Jørgen Gravning1 and John Kjekshus2,*

1 Institute for Surgical Research, Rikshospitalet University Hospital, Oslo, Norway
2 Department of Cardiology, Faculty of Medicine, University of Oslo, Norway

* Corresponding author. Tel: +47 23073677, Fax: +47 23073676, E-mail: john.kjekshus@medisin.uio.no

This editorial refers to ‘Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T’ by C.J. McCann et al. doi:10.1093/eurheartj/ehn363

The first 10% of the full text of this article appears below.

The use of biomarkers is one of the most important strategies for risk stratification among the increasing number of patients admitting to hospitals for acute coronary syndrome (ACS). The revolutionary benefit of using cardiac-specific troponins in this setting is the excellent specificity and sensitivity for myocardial injury, and several studies have confirmed the superiority of troponins as compared with creatine kinase-MB (CK-MB) for this purpose. The discovery of troponins as valuable markers for predicting mortality in unstable angina1 led to ‘The Joint European Society of Cardiology/American College of Cardiology Committee Consensus for the redefinition of myocardial . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T
Conor J. McCann, Ben M. Glover, Ian B.A. Menown, Michael J. Moore, Jane McEneny, Colum G. Owens, Bernie Smith, Peter C. Sharpe, Ian S. Young, and Jennifer A. Adgey
EHJ 2008 29: 2843-2850. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 HeartHome page
N C Edwards, H Routledge, and R P Steeds
T2-weighted magnetic resonance imaging to assess myocardial oedema in ischaemic heart disease
Heart, August 15, 2009; 95(16): 1357 - 1361.
[Abstract] [Full Text] [PDF]